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Objective: To compare different deﬁnitions of multimorbidity to identify patients with higher health care
resource utilization.
Patients and Methods: We used amultinational retrospective cohort including 147,806medical inpatients
discharged from 11 hospitals in 3 countries (United States, Switzerland, and Israel) between January 1, 2010,
and December 31, 2011. We compared the area under the receiver operating characteristic curve (AUC) of 8
deﬁnitions of multimorbidity, based on International Classiﬁcation of Diseases codes deﬁning health condi-
tions, the Deyo-Charlson Comorbidity Index, the Elixhauser-van Walraven Comorbidity Index, body sys-
tems, or Clinical Classiﬁcation Software categories to predict 30-day hospital readmission and/or prolonged
length of stay (longer than or equal to the country-speciﬁc upper quartile). We used a lower (yielding
sensitivity 90%) and an upper (yielding speciﬁcity 60%) cutoff to create risk categories.
Results: Deﬁnitions had poor to fair discriminatory power in the derivation (AUC, 0.61-0.65) and
validation cohorts (AUC, 0.64-0.71). The deﬁnitions with the highest AUC were number of (1) health
conditions with involvement of 2 or more body systems, (2) body systems, (3) Clinical Classiﬁcation
Software categories, and (4) health conditions. At the upper cutoff, sensitivity and speciﬁcity were 65% to
79% and 50% to 53%, respectively, in the validation cohort; of the 147,806 patients, 5% to 12% (7474 to
18,008) were classiﬁed at low risk, 38% to 55% (54,484 to 81,540) at intermediate risk, and 32% to 50%
(47,331 to 72,435) at high risk.
Conclusion: Of the 8 deﬁnitions of multimorbidity, 4 had comparable discriminatory power to identify
patients with higher health care resource utilization. Of these 4, the number of health conditions may
represent the easiest deﬁnition to apply in clinical routine. The cutoff chosen, favoring sensitivity or
speciﬁcity, should be determined depending on the aim of the deﬁnition.
ª 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/) n Mayo Clin Proc Inn Qual Out 2020;4(1):40-49W ith the increase in life expec-tancy, multimorbidity affects anincreasing number of patients.1-5
Given its association with higher health care
resource utilization, polypharmacy, and bad
quality of life, it represents a signiﬁcant
burden for patients and health care sys-
tems.6-12 Its deﬁnition remains nonethelessMayo Clin Proc Inn Qual Out n February 20
rg n ª 2019 Mayo Foundation for Medical Education and Research
the CC BY-NC-Nnot well standardized.5,7 Although the World
Health Organization (WHO) and the National
Institute for Health and Care Excellence
(NICE) guidelines deﬁne multimorbidity as 2
or more chronic conditions,13,14 we still lack
selection criteria for the conditions to include,
particularly on how to differentiate acute and
chronic conditions.5-8 Consequently, the20;4(1):40-49 n https://doi.org/10.1016/j.mayocpiqo.2019.09.002
. Published by Elsevier Inc. This is an open access article under
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
MULTIMORBIDITY DEFINITIONS AND HEALTH CARE UTILIZATIONnumber and types of conditions assessed vary
across most studies, making them difﬁcult to
compare.5-7
The prevalence of multimorbidity and its
consequences are unsurprisingly inﬂuenced
by the deﬁnition used. Recent reviews under-
lined the need of standardizing the assessment
of multimorbidity and of conducting studies
to test the best cutoffs for the number and
types of conditions to identify patients with
higher burden of multimorbidity because the
cutoffs chosen and the accuracy of speciﬁc def-
initions of multimorbidity may differ accord-
ing to the outcome assessed.5-7 For example,
deﬁnitions of multimorbidity developed to
assess mortality, such as the Charlson Comor-
bidity Index, may not be accurate to assess the
risk of other adverse health outcomes, such as
hospital readmission.6,15
Our objective for this study was to eval-
uate and compare the performance of different
deﬁnitions of multimorbidity to identify pa-
tients with higher health care resource utiliza-
tion, assessed as hospital readmission and
prolonged length of stay (LOS), with the
goal to standardize multimorbidity deﬁnition.
Our speciﬁc aims were to (1) compare the
discriminatory power of the deﬁnitions, (2)
identify for each deﬁnition of multimorbidity
a lower cutoff favoring sensitivity and an up-
per cutoff favoring speciﬁcity to classify the
patients at low, intermediate, or high risk of
higher health care resource utilization and
that may be used depending on the context
and purpose of using the deﬁnition, and (3)
compare those deﬁnitions with WHO/NICE
guidelines’ deﬁnition of multimorbidity.PATIENTS AND METHODS
Study Design
We used a retrospective multinational cohort
including all 147,806 medical inpatients dis-
charged from 11 hospitals in 3 countries
(United States, Switzerland, and Israel) be-
tween January 1, 2010, and December 31,
2011. The cohort included only patients
admitted to a medical ward and discharged
home or to a nursing home because the study
was designed to investigate hospital readmis-
sions in medical inpatients.16 To minimize
the risk of including observation stays, we
further included only patients with a hospitalMayo Clin Proc Inn Qual Out n February 2020;4(1):40-49 n https:/
www.mcpiqojournal.orgLOS of 1 day or more. We randomly selected
4 hospitals in the United States, 2 hospitals in
Switzerland, and 1 hospital in Israel to develop
the deﬁnitions of multimorbidity and the
remaining 3 US hospitals and 1 Swiss hospital
to validate them. Reporting is in accordance
with the Strengthening the Reporting of
Observational Studies in Epidemiology
(STROBE) statement.17
The institutional review board of each
participating site reviewed the study and
determined it to be nonehuman subjects
research, as it involved a secondary analysis
of anonymized data.
Classiﬁcation of Diagnoses
We used International Classiﬁcation of Diseases
(ICD) diagnosis codes to deﬁne the different
health conditions. First, we used the Clinical
Classiﬁcation Software (CCS) to merge the
health conditions into 285 exclusive cate-
gories.18 Second, we used the Chronic Condi-
tion Indicator (CCI) to classify the health
conditions as chronic or not chronic, as well
as into 18 exclusive body system categories.19
The CCI deﬁnes a condition as chronic if it
lasts 12 months or longer and places limita-
tions on self-care, independent living, and so-
cial interactions and/or results in the need for
ongoing intervention with medical products,
services, and special equipment. Both the
CCS and the CCI have been developed by
the Healthcare Cost and Utilization Project, a
federal-state-industry partnership sponsored
by the Agency for Healthcare Research and
Quality,18,19 and are available for ICD, Ninth
Revision (ICD-9) and ICD, Tenth Revision
(ICD-10) codes. Finally, we used the Deyo-
Charlson Comorbidity Index and the
Elixhauser-van Walraven Comorbidity Index
based on enhanced ICD-9, Clinical Modiﬁcation
and ICD-10 codes.15,20-23 During the time of
the study, the United States and Israel used
ICD-9 and Switzerland used ICD-10.
Deﬁnitions of Multimorbidity
We assessed 8 deﬁnitions of multimorbidity:
(1) 2 or more distinct body system categories
and number of health conditions, (2) 2 or
more distinct body system categories and
number of chronic health conditions, (3)
number of distinct body system categories,
(4) number of CCS categories, (5) number of/doi.org/10.1016/j.mayocpiqo.2019.09.002 41
TABLE 1. Baseline Characteristics of the Study Populationa,b
Characteristic
Total population
(N¼147,806)
Derivation cohort
(n¼ 92,071)
Validation cohort
(n¼ 55,735)
Age (y) 63 (50-75) 65 (51-77) 60 (47-72)
Men 71,175 (48.2) 44,090 (47.9) 27,085 (48.6)
Country
United States 89,268 (60.4) 42,306 (45.9) 46,962 (84.3)
Switzerland 42,739 (28.9) 33,966 (36.9) 8773 (15.7)
Israel 15,799 (10.7) 15,799 (17.2) 0 (0)
Description of multimorbidity
Number of health conditions 9 (5-13) 8 (4-12) 10 (6-14)
Number of chronic health conditions 5 (3-7) 4 (2-7) 5 (3-8)
Number of CCS categories 6 (4-9) 6 (3-9) 7 (5-10)
Number of body system categories 4 (3-6) 4 (2-6) 5 (3-7)
Deyo-Charlson Comorbidity Index 2 (0-3) 1 (0-3) 2 (0-3)
Elixhauser-van Walraven Comorbidity Index 5 (0-12) 5 (0-11) 5 (0-12)
Hospitalization characteristics
Length of stay (d) 4 (3-8) 4 (3-5) 4 (3-8)
Number of admissions in the past year 0 (0-2) 0 (0-2) 0 (0-2)
aCCS ¼ Clinical Classiﬁcation Software; IQR ¼ interquartile range.
bData are presented as median (IQR) or No. (percentage) of patients.
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42health conditions, (6) number of chronic
health conditions, (7) Deyo-Charlson Comor-
bidity Index, and (8) Elixhauser-van-
Walraven Comorbidity Index.
Outcomes
Our primary outcome was a composite end
point including any readmission to the same
hospital within 30 days after discharge and/or
a prolonged LOS, deﬁned as a stay longer
than or equal to country-speciﬁc upper
(75%) quartile. Secondary outcomes were the
single components of the primary outcome:
(1) any readmission to the same hospital
within 30 days after discharge and (2) a pro-
longed LOS. We used country-speciﬁc LOS
because the LOS differed between the coun-
tries included in the study (longer LOS in
Switzerland than in the United States or in
Israel).24,25
Statistical Analyses
We present baseline characteristics as median
with interquartile range (IQR) for continuous
variables and proportions for categorical vari-
ables. We calculated the discriminatory power
of the 8 different deﬁnitions of multimorbidity
in both the derivation and validation cohorts
using the area under the receiver operatingMayo Clin Proc Inn Qual Out n February 20characteristic curve (AUC), presented with
95% CIs.26 Then we calculated the sensitivity,
speciﬁcity, positive predictive value, negative
predictive value, and positive and negative
likelihood ratios of the different deﬁnitions
of multimorbidity at all possible cutoff values
in the derivation cohort. For each deﬁnition,
we then identiﬁed a lower cutoff optimizing
sensitivity and an upper cutoff optimizing
speciﬁcity, allowing us to build 3 risk cate-
gories (low, intermediate, and high) of higher
health care resource utilization. We deﬁned
the lower cutoff as having a sensitivity of at
least 90% in order to minimize the rate of
false negatives, ie, the number of patients
with multimorbidity who would be missed.
If several cutoffs met this criterion, we chose
the cutoff with the best speciﬁcity. We deﬁned
the upper cutoff as having a speciﬁcity of at
least 60% in order to minimize the rate of
false positives and optimize the identiﬁcation
of patients with true multimorbidity (true pos-
itives). If several cutoffs met this criterion, we
chose the cutoff with the best sensitivity. We
then used the validation cohort to validate
the lower and upper cutoffs identiﬁed in the
derivation cohort by computing the test char-
acteristics. We used the DeLong test in the
derivation and validation cohorts separately20;4(1):40-49 n https://doi.org/10.1016/j.mayocpiqo.2019.09.002
www.mcpiqojournal.org
TABLE 2. Performance of the Different Deﬁnitions of Multimorbidity for the Primary Outcome of Readmission and/or Prolonged Length of
Stay in the Derivation and Validation Cohortsa,b
Deﬁnition of multimorbidity
AUC (95% CI) in the
derivation cohort
AUC (95% CI) in the
validation cohort
Cutoff favoring
sensitivityc
Cutoff favoring
speciﬁcityc
2 Body system categories and number of
health conditions
0.65 (0.643-0.651)d 0.71 (0.706-0.715)e 3 9
2 Body system categories and number of chronic
health conditions
0.61 (0.606-0.614)f 0.64 (0.634-0.644)e 1 6
Number of distinct body system categories 0.65 (0.649-0.656)g 0.71 (0.700-0.709)h 2 5
Number of CCS categories 0.65 (0.648-0.656)g 0.71 (0.704-0.714)i 2 7
Number of health conditions 0.65 (0.645-0.653)j 0.71 (0.706-0.715)i 3 9
Number of chronic health conditions 0.61 (0.605-0.613)k 0.64 (0.633-0.642)e 1 6
Deyo-Charlson Comorbidity Index 0.62 (0.611-0.618)f,k 0.64 (0.637-0.646)e,l,m NAn 6
Elixhauser-Van-Walraven Comorbidity Index 0.62 (0.611-0.619)f,k 0.65 (0.643-0.653)m 0 6
aAUC ¼ area under the receiver operating characteristic curve; CCS ¼ Clinical Classiﬁcation Software; NA ¼ not available.
bProlonged length of stay was deﬁned as a length of stay as long as or longer than the country-speciﬁc upper quartile (75%).
cThe cutoff values relate to the number of items in the respective deﬁnitions of multimorbidity. We deﬁned the lower cutoff as having a sensitivity of 90%. If several cutoffs
met this criterion, we chose the cutoff with the best speciﬁcity. We deﬁned the upper cutoff as having a speciﬁcity of 60%. If several cutoffs met this criterion, we chose the
cutoff with the best sensitivity.
d-mThese AUCs were statistically signiﬁcantly different (P<.05) according to DeLong test conducted separately in the derivation and validation data sets. P values adjusted for
multiple comparisons using Bonferroni correction.
nThere was no cutoff with 90% sensitivity for the Deyo-Charlson Comorbidity Index except for a score of zero, which would have resulted in one group of patients only.
MULTIMORBIDITY DEFINITIONS AND HEALTH CARE UTILIZATIONto compare the different deﬁnitions of multi-
morbidity. Finally, we compared the perfor-
mance of these 8 deﬁnitions at the identiﬁed
cutoffs with the historical deﬁnition of multi-
morbidity, ie, the presence of 2 or more
chronic health conditions. The lower and up-
per cutoffs were determined for the primary
outcome ﬁrst and then used to assess the per-
formance of the deﬁnitions for the secondary
outcomes in the derivation and validation
cohorts.
All analyses were performed using R
version 3.4.4 (R Project for Statistical
Computing).
RESULTS
The median age of the 147,806 study patients
was 63 years (IQR, 50-75 years), 48.2% of
whom (71,175) were men (Table 1). The me-
dian number of health conditions and chronic
health conditions were 9 (IQR, 5-13) and 5
(IQR, 3-7), respectively. After random selec-
tion of the hospitals, 92,071 of the 147,806
patients (62.3%) were included in the deriva-
tion cohort and the remaining 55,735 patients
(37.7%) in the validation cohort. The median
age was lower in the validation cohort than in
the derivation cohort (60 vs 65 years).Mayo Clin Proc Inn Qual Out n February 2020;4(1):40-49 n https:/
www.mcpiqojournal.orgPerformance of the Different Deﬁnitions of
Multimorbidity for the Primary Outcome
Deﬁnitions had poor to fair discriminatory po-
wer, with an AUC of 0.61 to 0.65 in the deri-
vation cohort and 0.64 to 0.71 in the
validation cohort (Table 2 and Figure; details
in Supplemental Table 1, available online at
http://www.mcpiqojournal.org). The deﬁni-
tions based on the number of (1) health con-
ditions with 2 or more body system
categories, (2) body system categories, (3)
CCS categories, and (4) health conditions per-
formed the best, with AUCs of 0.65 to 0.65 in
the derivation cohort and 0.71 to 0.71 in the
validation cohort.
We could identify a lower and an upper
cutoff meeting our predeﬁned sensitivity
(90%) and speciﬁcity (60%) criteria for all
deﬁnitions except for the deﬁnition based on
the Deyo-Charlson Comorbidity Index (sensi-
tivity always <90%). For the 4 deﬁnitions
that performed best, both sensitivity and spec-
iﬁcity were around 60% at the upper cutoff in
the derivation cohort. In the validation cohort,
the sensitivity was higher (75%-79%), but the
speciﬁcity was lower (50%-53%). At the lower
cutoff, the deﬁnition based on the number of
chronic health conditions performed best/doi.org/10.1016/j.mayocpiqo.2019.09.002 43
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44with a sensitivity of 96% in the derivation
cohort and 99% in the validation cohort, but
at the cost of a very low speciﬁcity (8% and
4%, respectively). The historical deﬁnition of
multimorbidity had a sensitivity of 89% and
95%, for a speciﬁcity of 20% and 12% in the
derivation and validation cohorts, respectively.
Risk Categories
In the derivation cohort (n¼92,071), 6.5% to
15.8% of the patients (5995 to 14,209) were
classiﬁed in the low-risk category and 30.1%
to 45.6% (27,701 to 42,016) in the high-risk
category, depending on the deﬁnition of multi-
morbidity (Table 3). In the validation cohort
(n¼55,735), the proportions of patients in
the low-risk category were lower (2.7%-8.0%
[1479 to 4483]), while up to 31.4% to 58.9%
(17,525 to 32,206) were classiﬁed at high
risk. In the total cohort (N¼147,806), the
smallest proportion of patients at low risk was
found for the deﬁnition using the number of
chronic health conditions (5.0% [7474]) and
the largest proportion for the deﬁnition using
the number of health conditions with 2 or
more body system categories (12.4%
[18,008]). At the opposite, the smallest propor-
tion of patients at high risk was found for the
deﬁnition using the Deyo-Charlson Comorbid-
ity Index (30.6% [45,226]) and the largest pro-
portion for the deﬁnitions using the number of
health conditions with 2 or more body system
categories or the number of health conditions
alone (both 50.0% [72,375 and 72,435]).
Performance of the Different Deﬁnitions of
Multimorbidity for 30-Day Readmission
In the derivation cohort, the AUC for 30-day
readmission was 0.57 to 0.58 (95% CI, 0.56-
0.61; Supplemental Table 2 and Supplemental
Figure 1, available online at http://www.
mcpiqojournal.org). In the validation cohort,
the AUC varied between 0.57 (95% CI, 0.56-
0.58) and 0.63 (95% CI, 0.62-0.63). The deﬁni-
tion based on the Deyo-Charlson Comorbidity
Index performed best (AUC, 0.63; 95% CI,
0.62-0.63). Only the deﬁnitions based on the
number of CCS categories, health conditions,
chronic health conditions, and Elixhauser-van-
Walraven Comorbidity Index reached a sensi-
tivity of 90% or higher using the lower cutoff
in the derivation cohort, while all deﬁnitions,
except the deﬁnition based on Deyo-CharlsonMayo Clin Proc Inn Qual Out n February 20Comorbidity Index (no lower cut-off), showed
a sensitivity of 94% or higher in the validation
cohort. For the upper cutoff, only the deﬁnitions
based on the (1) number of chronic health con-
ditions with 2 or more body system categories,
(2) Deyo-Charlson Comorbidity Index, and (3)
number of chronic health conditions in the deri-
vation cohort and only the deﬁnition based on
the Deyo-Charlson Comorbidity Index in the
validation cohort reached the 60% or higher
speciﬁcity threshold.
Performance of the Different Deﬁnitions of
Multimorbidity for Prolonged LOS
The AUC for prolonged LOS varied between
0.60 (95% CI, 0.60-0.61) and 0.67 (95% CI,
0.67-0.68) in the derivation cohort and be-
tween 0.62 (95% CI, 0.61-0.62) and 0.76
(95% CI, 0.75-0.76) in the validation cohort
(Supplemental Table 3 and Supplemental
Figure 2, available online at http://www.
mcpiqojournal.org). The deﬁnition based on
the number of CCS categories performed best
(AUC, 0.76; 95%CI, 0.75-0.76). All deﬁnitions
showed a sensitivity of 92% or greater for the
lowest cutoff in both the derivation and valida-
tion cohorts, except the deﬁnition based on
Deyo-Charlson Comorbidity Index (no lower
cut-off). For the upper cutoff, the speciﬁcity
was 59% to 73% in the derivation cohort, while
it varied more in the validation cohort (47%-
72%).
DISCUSSION
In a large multinational cohort, we found that
8 deﬁnitions of multimorbidity had poor to
fair discriminatory power to identify patients
with higher health care resource utilization.
Four of these deﬁnitions performed similarly
well and better than the other 4. To our
knowledge, this is the ﬁrst study comparing
deﬁnitions of multimorbidity in relationship
to health care resource utilization and identi-
fying different cutoffs favoring sensitivity or
speciﬁcity. Simple deﬁnitions performed
equally well as more complex ones. The selec-
tion of a lower and an upper cutoff allowed
classiﬁcation of the patients into 3 risk cate-
gories of health care resource utilization.
Although both the WHO and NICE guide-
lines deﬁned multimorbidity as 2 or more
chronic health conditions, previous reviews
found that a lack of standardization remains20;4(1):40-49 n https://doi.org/10.1016/j.mayocpiqo.2019.09.002
www.mcpiqojournal.org
MULTIMORBIDITY DEFINITIONS AND HEALTH CARE UTILIZATIONconcerning which and how many conditions
to include, particularly concerning the distinc-
tion between acute and chronic conditions.6,7
In our study, the lower cutoff, favoringSp
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46categorizing systems. This ﬁnding underlines
the importance of clearly deﬁning which
health conditions to include in a deﬁnition
before setting a speciﬁc cutoff.
Interestingly, the lower cutoff was 1 or
more for the deﬁnition based on chronic
health conditions, and not 2 or more as
deﬁned by the WHO and NICE guide-
lines.13,14 Considering a single condition may
be self-contradictory with the concept of mul-
timorbidity. However, this ﬁnding suggests
that assessing only chronic health conditions
may help improve sensitivity to identify multi-
morbidity. A deﬁnition using only chronic
health conditions with a cutoff of 1 or more
may thus be preferred when high sensitivity
is most important but low speciﬁcity not an
issue, such as for implementing simple,
broadly available and cheap preventive inter-
ventions, which should reach all patients
who possibly have multimorbidity. With this
aim in mind and to allow study comparability,
a rigorous differentiation between acute and
chronic health conditions is required, but not
consequently done.5,7 A standardized classiﬁ-
cation tool such as the CCI may be useful
and minimize subjectivity.19
All lower cutoffs, whichwere comparable to
those previously used to deﬁnemultimorbidity,
were characterized by a particularly poor spec-
iﬁcity, whereas the upper cutoffs were far higher
than usual cutoffs, up to 9 or more for all health
conditions.6,7 This ﬁnding suggests that usual
deﬁnitions of multimorbidity favor sensitivity
over speciﬁcity in relationship to health care
resource utilization andmay thus not accurately
identify patients with multimorbidity at higher
risk of health care utilization. Higher cutoffs
probably select patients with greater burden of
multimorbidity requiring particular atten-
tion.5,7 Because themost effective preventive in-
terventions to lower readmission rates areFIGURE. Area area under the receiver operating chara
multimorbidity to predict any 30-day hospital readmissio
longer than or equal to the country-speciﬁc upper quart
distinct body system categories and number of health
categories and number of chronic health conditions. C
Number of Clinical Classiﬁcation Software categories. E,
health conditions. G, Deyo-Charlson Comorbidity Inde
Mayo Clin Proc Inn Qual Out n February 20complex and intensive, using higher and more
speciﬁc cutoffs may be useful to select patients
most likely to beneﬁt.27 A classiﬁcation of pa-
tients into 3 risk categories may help to select
patients for speciﬁc interventions.
Although the Deyo-Charlson Comorbidity
Index remains often used to assess multimor-
bidity, it may not always be appropriate because
of its poor sensitivity.6,28 Furthermore, because
this index was developed and validated to pre-
dict mortality,15,28 it may not be valid to assess
other health outcomes. Although previous
studies found an association between the Elix-
hauser Comorbidity Index and health care
resource utilization,29,30 its accuracy was rather
poor in our cohort, suggesting that complex
assessment of multimorbidity is not better
than more simple measurements.
Because combining 2 different measures of
multimorbidity may help to improve the accu-
racy, we tested deﬁnitions combining all or
only chronic health conditions with 2 or
more body systems involved. However, these
deﬁnitions did not perform better than deﬁni-
tions without body system categories and had
the same lower and upper cutoffs for the num-
ber of conditions. This ﬁnding suggests that
making the deﬁnition more complex does
not improve its accuracy, so more simple def-
initions may be preferred.
The 4 deﬁnitions that performed best for
the primary outcome were also those that per-
formed best for the secondary outcomes.
However, the different deﬁnitions performed
better to identify patients at higher risk of pro-
longed LOS than of readmission. Further-
more, the deﬁnition that performed best was
different for these 2 outcomes (number of
CCS categories for prolonged LOS and num-
ber of health categories for 30-day readmis-
sion), suggesting that some deﬁnitions are
better than others for different outcomes.cteristic curve (AUC) of the different deﬁnitions of
n and/or a prolonged length of stay (deﬁned as a stay
ile [75%]) in the derivation cohort. A, Two or more
conditions. B, Two or more distinct body system
, Number of distinct body system categories. D,
Number of health conditions. F, Number of chronic
x. H, Elixhauser-van-Walraven Comorbidity Index.
20;4(1):40-49 n https://doi.org/10.1016/j.mayocpiqo.2019.09.002
www.mcpiqojournal.org
TABLE 3. Observed Proportions of Patients in Risk Categories According to Deﬁnitions of Multimorbidity for the Primary Outcome of Hospital
Readmission and/or Prolonged Length of Stay in the Derivation, Validation, and Total Cohortsa,b
Deﬁnition of multimorbidity
Risk category
Low Intermediate High
Derivation cohort (n¼92,071)
2 Body system categories and number of health conditions 14,209 (15.8) 35,782 (39.7) 40,182 (44.5)
2 Body system categories and number of chronic health conditions 13,245 (14.4) 45,445 (49.4) 33,379 (36.2)
Number of distinct body system categories 11,695 (12.7) 39,632 (43.1) 40,730 (44.2)
Number of CCS categories 8640 (9.4) 42,472 (46.1) 40,949 (44.5)
Number of health conditions 11,083 (12.3) 38,861 (43.1) 40,229 (44.6)
Number of chronic health conditions 5995 (6.5) 52,609 (57.1) 33,465 (36.4)
Deyo-Charlson Comorbidity Index 64,369 (69.9)c 27,701 (30.1)
Elixhauser-van-Walraven Comorbidity Index 6798 (7.4) 43,256 (47.0) 42,016 (45.6)
Validation cohort (n¼55,735)
2 Body system categories and number of health conditions 3799 (6.9) 18,702 (34.2) 32,193 (58.9)
2 Body system categories and number of chronic health conditions 3613 (6.5) 26,851 (48.2) 25,267 (45.3)
Number of distinct body system categories 2893 (5.2) 20,349 (36.5) 32,489 (58.3)
Number of CCS categories 1940 (3.5) 22,419 (40.2) 31,371 (56.3)
Number of health conditions 2721 (5.0) 19,767 (36.1) 32,206 (58.9)
Number of chronic health conditions 1479 (2.7) 28,931 (51.9) 25,321 (45.4)
Deyo-Charlson Comorbidity Index 38,209 (68.6)c 17,525 (31.4)
Elixhauser-Van-Walraven Comorbidity Index 4483 (8.0) 23,847 (42.8) 27,404 (49.2)
Total cohort (N¼147,806)
2 Body system categories and number of health conditions 18,008 (12.4) 54,484 (37.6) 72,375 (50.0)
2 Body system categories and number of chronic health conditions 16,858 (11.4) 72,296 (48.9) 58,650 (39.7)
Number of distinct body system categories 14,588 (9.9) 59,981 (40.6) 73,233 (49.5)
Number of CCS categories 10,580 (7.2) 64,891 (43.9) 72,320 (48.9)
Number of health conditions 13,804 (9.5) 58,628 (40.5) 72,435 (50.0)
Number of chronic health conditions 7474 (5.0) 81,540 (55.2) 58,790 (39.8)
Deyo-Charlson Comorbidity Index 102,578 (69.4)c 45,226 (30.6)
Elixhauser-van-Walraven Comorbidity Index 11,281 (7.6) 67,103 (45.4) 69,421 (47.0)
aCCS ¼ Clinical Classiﬁcation Software.
bData are presented as percentages of the cohort. The low-, intermediate-, and high-risk categories were deﬁned using the cutoffs identiﬁed in Table 2. Patients with a
number of items lower than the lower cutoff were classiﬁed at low risk, those with a number higher than or equal to the upper cutoff at high risk, and those with a number
between the lower and the upper cutoffs at intermediate risk. For example, for the number of health conditions, 0 to 2 health conditions corresponds to low risk, 3 to 8
health conditions to intermediate risk, and 9 or more health conditions to high risk of multimorbidity.
cFor the Deyo-Charlson Comorbidity Index, there were only 2 risk categories, as we could not identify a lower cutoff.
MULTIMORBIDITY DEFINITIONS AND HEALTH CARE UTILIZATIONTherefore, a different deﬁnition may be
preferred to identify patients at higher risk of
prolonged LOS or of readmission.
Although different cutoffs and deﬁnitions
may be used according to the purpose of an
assessment, thismay not apply to the evaluation
of multimorbidity prevalence.6,7,28,31 In fact,
heterogeneity in the types and number of condi-
tions assessed (4 to 185 in previous studies)
inevitably resulted in poorly comparable re-
sults, with reported prevalences of 23% to
99%.1-3,7,32,33 Further research and experts’
consensus is required to delineate a more uni-
form deﬁnition of multimorbidity for preva-
lence studies in particular. Doing so, the highMayo Clin Proc Inn Qual Out n February 2020;4(1):40-49 n https:/
www.mcpiqojournal.orgsensitivity but poor speciﬁcity of common def-
initions should be challenged to avoid overesti-
mating the prevalence of multimorbidity.
Our study had several limitations. First,
using ICD codes is subject to coding quality,
possibly leading to underreporting.34,35 How-
ever, ICD codes are used most often because
they are the simplest and most standardized
way to collect diagnoses. Second, Switzerland
used ICD-10 codes, while the United States
and Israel used ICD-9 codes; nevertheless,
because the classiﬁcation systems were avail-
able for ICD-9 and ICD-10, a signiﬁcant
impact is rather unlikely. Third, other relevant
components of multimorbidity, such as/doi.org/10.1016/j.mayocpiqo.2019.09.002 47
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48psychological, social, and environmental fac-
tors,7,36 as well as differences in health care
systems, may have impacted the effect of mul-
timorbidity. However, such aspects are chal-
lenging to assess; a standardized deﬁnition to
be used independently of these factors and
across health care systems may thus be useful.
Finally, we included only readmissions to the
same hospital, so we may have missed read-
missions to other hospitals.
Our study also has several strengths. First,
we used 8 different deﬁnitions of multimorbid-
ity, as well as standardized classiﬁcation tools
allowing reproducibility.18,19 Second, our pri-
mary outcome included both readmissions
and prolonged LOS, allowing a more holistic
assessment of health care resource utilization.
Third, we identiﬁed lower and upper cutoffs
that may be used depending on the purpose
of using a deﬁnition of multimorbidity. Finally,
we used a large and multinational cohort,
increasing the generalizability of our ﬁndings.CONCLUSION
In this study, we found that 8 deﬁnitions of
multimorbidity had poor to fair discriminatory
power, but 4 of them, based on ICD codes,
performed similarly well and better than the
other 4 to identify patients with higher health
care resource utilization. Therefore, one may
favor the use of the deﬁnition based on the
number of health conditions only, because it
is simple to apply as ICD codes are easily avail-
able. To allow comparability across studies,
standardizing the number and types of condi-
tions to include in the deﬁnition of multimor-
bidity is required when measuring its
prevalence. However, when evaluating the
relationship of multimorbidity with adverse
health outcomes, the cutoff and deﬁnition
chosen should be determined depending on
the speciﬁc aim of the study.ACKNOWLEDGMENTS
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